Oncotelic Therapeutics Inc (OTLC)

$0.07 0.00 (-2.40%)
Market Cap 29.48M
Revenue (ttm) 0.00
Net Income (ttm) -4.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.72
Volume 283,300
Avg Vol 138,156
Day's Range N/A - N/A
Shares Out 442.60M
Stochastic %K 0%
Beta -0.66
Analysts Strong Buy
Price Target $4.00

Company Profile

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatme...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 635 7000
Fax: 650 635 7001
Address:
29397 Agoura Road, Suite 107, Agoura Hills, United States
NetworkNewsWire
NetworkNewsWire Apr. 2 at 5:48 PM
BioMedNewsBreaks – $OTLC Partners with TechForce Robotics to Advance AI-Enabled GMP Automation Platform https://ibn.fm/ug7oX
0 · Reply
ckruel
ckruel Apr. 2 at 2:06 PM
$OTLC https://finance.yahoo.com/sectors/healthcare/articles/oncotelic-therapeutics-announces-strategic-partnership-123000782.html
0 · Reply
ckruel
ckruel Apr. 2 at 2:03 PM
$OTLC The platform supports automated material handling, integrated vision and monitoring systems, PDAOAI-Enhanced deviation detection, and generation of time-stamped documentation aligned with GMP requirements. The system is designed to continuously improve through data-driven insights and operational feedback loops. This announcement follows the execution of a joint development, manufacturing, and licensing agreement between the parties, establishing a framework for ongoing collaboration, production scaling, and commercialization of PDAOAI-Enhanced robotic systems. Market Opportunity As regulatory scrutiny intensifies and pharmaceutical manufacturers seek to reduce reliance on manual processes, PDAOAI-Enhanced automation is emerging as a critical layer for real-time compliance. Oncotelic believes this platform is well-positioned to address growing demand for intelligent, scalable, and compliant solutions across pharmaceutical manufacturing and other regulated industries.
0 · Reply
ckruel
ckruel Apr. 2 at 2:02 PM
$OTLC “This commercialization represents a significant step forward in bridging PDAOAI and automation within regulated pharmaceutical environments,” said Dr. Vuong Trieu, chairman and Chief Executive Officer of Oncotelic. “After years of development, we are now positioned to advance our transformative solution toward commercialization that can enhance compliance, reduce operational risk, and improve efficiency across the industry.” Ried Floco, president of TechForce Robotics, added, “Our collaboration with Oncotelic demonstrates the power of combining advanced AI with purpose-built robotics systems. With our manufacturing and deployment capabilities, we are now working toward scaling this solution for real-world applications.”
0 · Reply
ckruel
ckruel Apr. 2 at 1:58 PM
$OTLC Not the news one might expect… herapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, today announced that it has entered into a strategic partnership with TechForce Robotics, Inc. (“TechForce”) to advance the commercialization of its PDAOAI-enabled, GMP-compliant robotics platform. This milestone reflects the culmination of several years of research and development efforts, resulting in an integrated platform designed to combine Oncotelic’s proprietary PDAOAI capabilities with TechForce’s robotics hardware and manufacturing expertise.
0 · Reply
Bunster
Bunster Apr. 1 at 7:41 PM
$OTLC NO SPIN Not filing your 10k by the due date and needing an extension aint good. its just common sense
0 · Reply
ckruel
ckruel Apr. 1 at 1:29 PM
$OTLC The notification emphasizes the company’s intent to remain in compliance with SEC reporting requirements despite the delay. The Form 12b-25 is signed on behalf of Oncotelic Therapeutics, Inc. by Chief Financial Officer Amit Shah on March 31, 2026, underscoring executive-level responsibility for both the late-filing notice and the forthcoming annual report.
0 · Reply
ckruel
ckruel Apr. 1 at 1:28 PM
$OTLC while the filing is late, management does not foresee major surprises in the financials versus last year, though investors should remember that this expectation is inherently forward-looking. Actual results, once the Form 10-K (Yearly Report) is filed, may still differ depending on final accounting judgments and audit procedures.
0 · Reply
Bunster
Bunster Apr. 1 at 2:33 AM
$OTLC The company is working on and unable to compile the necessary financial info required to prepare a complete filing .Thus the company would be unable to file the annual report in a timely manner without unreasonable effort or expense.
0 · Reply
ckruel
ckruel Apr. 1 at 1:54 AM
$OTLC • Oncotelic delayed its 2025 Form 10-K (Yearly Report) due to ongoing financial data compilation. • The company expects timely filing within the SEC extension and foresees no major earnings changes.
0 · Reply
Latest News on OTLC
No data available.
NetworkNewsWire
NetworkNewsWire Apr. 2 at 5:48 PM
BioMedNewsBreaks – $OTLC Partners with TechForce Robotics to Advance AI-Enabled GMP Automation Platform https://ibn.fm/ug7oX
0 · Reply
ckruel
ckruel Apr. 2 at 2:06 PM
$OTLC https://finance.yahoo.com/sectors/healthcare/articles/oncotelic-therapeutics-announces-strategic-partnership-123000782.html
0 · Reply
ckruel
ckruel Apr. 2 at 2:03 PM
$OTLC The platform supports automated material handling, integrated vision and monitoring systems, PDAOAI-Enhanced deviation detection, and generation of time-stamped documentation aligned with GMP requirements. The system is designed to continuously improve through data-driven insights and operational feedback loops. This announcement follows the execution of a joint development, manufacturing, and licensing agreement between the parties, establishing a framework for ongoing collaboration, production scaling, and commercialization of PDAOAI-Enhanced robotic systems. Market Opportunity As regulatory scrutiny intensifies and pharmaceutical manufacturers seek to reduce reliance on manual processes, PDAOAI-Enhanced automation is emerging as a critical layer for real-time compliance. Oncotelic believes this platform is well-positioned to address growing demand for intelligent, scalable, and compliant solutions across pharmaceutical manufacturing and other regulated industries.
0 · Reply
ckruel
ckruel Apr. 2 at 2:02 PM
$OTLC “This commercialization represents a significant step forward in bridging PDAOAI and automation within regulated pharmaceutical environments,” said Dr. Vuong Trieu, chairman and Chief Executive Officer of Oncotelic. “After years of development, we are now positioned to advance our transformative solution toward commercialization that can enhance compliance, reduce operational risk, and improve efficiency across the industry.” Ried Floco, president of TechForce Robotics, added, “Our collaboration with Oncotelic demonstrates the power of combining advanced AI with purpose-built robotics systems. With our manufacturing and deployment capabilities, we are now working toward scaling this solution for real-world applications.”
0 · Reply
ckruel
ckruel Apr. 2 at 1:58 PM
$OTLC Not the news one might expect… herapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, today announced that it has entered into a strategic partnership with TechForce Robotics, Inc. (“TechForce”) to advance the commercialization of its PDAOAI-enabled, GMP-compliant robotics platform. This milestone reflects the culmination of several years of research and development efforts, resulting in an integrated platform designed to combine Oncotelic’s proprietary PDAOAI capabilities with TechForce’s robotics hardware and manufacturing expertise.
0 · Reply
Bunster
Bunster Apr. 1 at 7:41 PM
$OTLC NO SPIN Not filing your 10k by the due date and needing an extension aint good. its just common sense
0 · Reply
ckruel
ckruel Apr. 1 at 1:29 PM
$OTLC The notification emphasizes the company’s intent to remain in compliance with SEC reporting requirements despite the delay. The Form 12b-25 is signed on behalf of Oncotelic Therapeutics, Inc. by Chief Financial Officer Amit Shah on March 31, 2026, underscoring executive-level responsibility for both the late-filing notice and the forthcoming annual report.
0 · Reply
ckruel
ckruel Apr. 1 at 1:28 PM
$OTLC while the filing is late, management does not foresee major surprises in the financials versus last year, though investors should remember that this expectation is inherently forward-looking. Actual results, once the Form 10-K (Yearly Report) is filed, may still differ depending on final accounting judgments and audit procedures.
0 · Reply
Bunster
Bunster Apr. 1 at 2:33 AM
$OTLC The company is working on and unable to compile the necessary financial info required to prepare a complete filing .Thus the company would be unable to file the annual report in a timely manner without unreasonable effort or expense.
0 · Reply
ckruel
ckruel Apr. 1 at 1:54 AM
$OTLC • Oncotelic delayed its 2025 Form 10-K (Yearly Report) due to ongoing financial data compilation. • The company expects timely filing within the SEC extension and foresees no major earnings changes.
0 · Reply
ckruel
ckruel Mar. 30 at 7:08 PM
$OTLC • Oncotelic and its Sapu Nano unit are advancing oncology and neurological assets. • Sapu Nano will present its Deciparticle platform and Phase 1 oncology candidates at BIO-Europe Spring 2026.
0 · Reply
ckruel
ckruel Mar. 24 at 6:58 PM
$OTLC this video has an interesting bull bear thesis for otlc https://youtu.be/kcEoNtJYXmU?si=RpZg--21UyTRcc_J
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 24 at 6:36 PM
BioMedNewsBreaks – $OTLC To Present Deciparticle Platform And Pipeline At BIO-Europe Spring 2026 https://ibn.fm/oQGem
1 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 23 at 4:23 PM
BioMedNewsBreaks – $OTLC Subsidiary Sapu Nano To Present Everolimus Toxicology Data At SOT 2026 https://ibn.fm/DqFys
0 · Reply
ckruel
ckruel Mar. 23 at 2:27 PM
$OTLC https://www.otcmarkets.com/stock/OTLC/news/Sapu-Nano-to-Present-Everolimus-Toxicology-Data-at-SOT-2026-Annual-Meeting?id=514766
0 · Reply
ckruel
ckruel Mar. 20 at 4:39 PM
$OTLC this also should bring inst. investment
0 · Reply
ckruel
ckruel Mar. 20 at 4:38 PM
$OTLC this is from the analyst who has the $4 target . Read the last line, this event is gearing for the near future along with the reevaluation of OTLC’s balance sheet when the 45. Percent is applied, that is why I’m buying down here. OTLC: As we reported in our March 31 research note, OTLC entered into a joint venture, or JV, with Dragon Overseas Capital Ltd. (Dragon Overseas) and GMP Biotechnology Ltd. (GMP Bio). Dragon Overseas and GMP Bio are affiliated with Golden Mountain Partners (GMP). GMP Bio also has a wholly owned subsidiary, Sapu Therapeutics, LLC, which in turn has two wholly owned subsidiaries, namely Sapu Bioscience, LLC and Sapu Holdings, LLC. The plan of the JV is to develop and ultimately market OT-101, individually and/or in combination with other products, along with its JV partners. Also, the JV is intended to go public through an IPO at some time in the future. OTLC owns 45% of the JV and on its public debut could add multiples to the company’s market cap.
0 · Reply
ckruel
ckruel Mar. 16 at 6:51 PM
$OTLC volume 3 x the daily avg at 917,000
0 · Reply
ckruel
ckruel Mar. 16 at 5:17 PM
$OTLC Balance Sheet Action: Oncotelic has initiated an ASC-compliant valuation to determine how much of this new valuation can be formally recognized on its balance sheet. The company indicated that if this assessment confirms a higher value, they will record an upward adjustment, which would potentially lead to a "major fair-value uptick" and a "meaningful increase" in total assets and shareholder equity. Timing: The co. planned to complete this second independent U.S.-based valuation to support the remeasurement of its 45% equity interest as part of its forward-looking strategy entering 2026. This revaluation is designed to reflect the matured progress of Oncotelic's Deciparticle™ nanomedicine platform (specifically Sapu-003) and its transition toward financial recognition. The company is still navigating significant financial hurdles, including a low market cap and high dilution risk from convertible debt, which the co. is attempting to manage alongside this revaluation.
0 · Reply
ckruel
ckruel Mar. 16 at 5:14 PM
$OTLC Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is actively working to revalue its company based on a new, higher independent valuation of its joint venture (JV) partnership with GMP Bio. Financial Post Financial Post +1 Based on updates from late 2025 and early 2026, here is the breakdown of the revaluation: New Partnership Valuation: A third-party analysis (by Frost & Sullivan) of the GMP Bio joint venture pipeline, completed in Nov 2025, valued it at approximately $1.7 billion. Oncotelic's Implied Value: With a 45% stake in GMP Bio, Oncotelic’s proportional implied asset value is estimated at roughly $765 million.
0 · Reply
Mauisurfrider
Mauisurfrider Mar. 16 at 12:29 PM
$OTLC
0 · Reply
ckruel
ckruel Mar. 12 at 7:49 PM
$OTLC Just under 610 k vol so far today, twice the avg daily……
0 · Reply